A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

ID#: NCT05378529

Age: 18 - 85 years

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: April 19, 2022

End Date: May 22, 2023

Contact Information:
Amgen Call Center
866-572-6436
Summary: The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: - Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD - Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions
Eligibility:

Inclusion Criteria:

- Signed informed consent

- History of ASCVD

Exclusion Criteria:

- Participants known to be currently receiving investigational drug in a clinical study

- Participants with a diagnosis of end-stage renal disease or requiring dialysis

- Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment
Find a Clinical Trial